Improved survival with continuation of statins in bacteremic patients

Abstract

Objectives:Varying statin exposures in bacteremic patients have different impacts on mortality. Among patients with adherent statin use, we sought to evaluate the impact of statin continuation on inpatient mortality in bacteremic patients.Methods:A retrospective cohort study was conducted using Optum ClinformaticsTM with matched Premier Hospital data (October 2009–March 2013). Patients with a primary diagnosis of bacteremia and 6 months of continuous enrollment prior to the admission, receiving antibiotics at least 2 days of antibiotics during the first 3 days of admission, were selected for inclusion. Furthermore, patients demonstrating adherent statin use based on 90 days of continuous therapy prior to admission were included. We then compared those continuing statin therapy for at least the first 5 days after admission and those not continuing during the admission.Results:Simvastatin (53.2%) and atorvastatin (33.8%) were the most commonly used statins among the 633 patients who met our inclusion and exclusion criteria. Propensity score adjusted Cox proportional hazards regression models demonstrated significantly lower inpatient mortality among those continuing statin therapy compared with those not continuing (n = 232 vs 401, adjusted hazard ratio 0.25, 95% confidence interval 0.08–0.79).Conclusion:Among patients adherent to their statin therapy prior to a bacteremia hospitalization, continued statin use after admission increased survival by 75% compared with those not continuing.

Microbiological Status of Venous Leg Ulcers and Its Predictors: A Single-Center Cross-Sectional Study

“…The anti-inflammatory properties were independent of the lipid-lowering abilities of the statins. We did not evaluate the influence of statins on the course of infection, but almost all patients with hyperlipidaemia and atherosclerosis took them [ 37 , 38 , 39 , 40 , 41 ]. Statins may have resulted in a lower frequency of infections in patients with atherosclerosis.…”

Protective efficacy of statins in patients with Klebsiella pneumoniae bloodstream infection

“…On the other hand, Pawar et al (Pawar et al, 2018) found that continued statins use for at least two days after admission provided a survival benefit among bacteremia patients. Similar to our study, about 77% (21/91) of patients continued using statins for more than two days.…”